TY - STD TI - Kaufman HL, Atkins MB, Dicker AP, Jim HS, Garrison LP, Herbst RS, et al. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting. Journal for ImmunoTherapy of Cancer. 2017;5(1). ID - ref1 ER - TY - STD TI - Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Giacomo AMD, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with Nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA. 2018. ID - ref2 ER - TY - JOUR AU - Kakadia, S. AU - Yarlagadda, N. AU - Awad, R. AU - Kundranda, M. AU - Niu, J. AU - Naraev, B. PY - 2018 DA - 2018// TI - Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma JO - OncoTargets and Therapy VL - Volume 11 UR - https://doi.org/10.2147/OTT.S182721 DO - 10.2147/OTT.S182721 ID - Kakadia2018 ER - TY - JOUR AU - Ventola, C. L. PY - 2017 DA - 2017// TI - Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations JO - Pharmacy and Therapeutics VL - 42 ID - Ventola2017 ER - TY - JOUR AU - June, C. H. AU - Sadelain, M. PY - 2018 DA - 2018// TI - Chimeric Antigen Receptor Therapy JO - New England Journal of Meicine VL - 379 UR - https://doi.org/10.1056/NEJMra1706169 DO - 10.1056/NEJMra1706169 ID - June2018 ER - TY - BOOK AU - Andtbacka, R. H. AU - Kaufman, H. L. AU - Collichio, F. AU - Amatruda, T. AU - Senzer, N. AU - Chesney, J. PY - 2015 DA - 2015// TI - Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma PB - Current neurology and neuroscience reports CY - Journal of Clinical Oncology UR - https://doi.org/10.1200/JCO.2014.58.3377 DO - 10.1200/JCO.2014.58.3377 ID - Andtbacka2015 ER - TY - JOUR AU - Fabbri, R. AU - Macciocca, M. AU - Vicenti, R. PY - 2016 DA - 2016// TI - Doxorubicin and cisplatin induce apoptosis in ovarian stromal cells obtained from cryopreserved human ovarian tissue JO - Future Oncol VL - 12 UR - https://doi.org/10.2217/fon-2016-0032 DO - 10.2217/fon-2016-0032 ID - Fabbri2016 ER - TY - JOUR AU - Okhenhaug, K. AU - Graupera, M. AU - Vanhaeesbroceck, B. PY - 2016 DA - 2016// TI - Targeting Pi#K in cancer: Impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0716 DO - 10.1158/2159-8290.CD-16-0716 ID - Okhenhaug2016 ER - TY - STD TI - Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma | NEJM. N Engl J Med. 2010. ID - ref9 ER - TY - JOUR AU - Dharmaraj, N. AU - Piotrowski, S. L. AU - Huang, C. AU - Newton, J. M. AU - Golfman, L. S. AU - Hanoteau, A. AU - Koshy, S. T. AU - Li, A. W. AU - Pulikkathara, M. X. AU - Zhang, B. AU - Burks, J. K. AU - Mooney, D. J. AU - Lei, Y. L. AU - Sikora, A. G. AU - Young, S. PY - 2019 DA - 2019// TI - Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape JO - OncoImmunology VL - 8 UR - https://doi.org/10.1080/2162402X.2019.1568809 DO - 10.1080/2162402X.2019.1568809 ID - Dharmaraj2019 ER - TY - STD TI - Dutcher JP. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Current neurology and neuroscience reports. U.S. National Library of Medicine; 2002 [cited 2019 Jan 13]. ID - ref11 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crinò, L. AU - Eberhardt, W. E. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer JO - New England Journal of Medicine VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Yu, D. -. P. AU - Cheng, X. AU - Liu, Z. -. D. AU - Xu, S. -. F. PY - 2017 DA - 2017// TI - Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: meta-analysis and systematic review JO - Oncol Lett VL - 14 UR - https://doi.org/10.3892/ol.2017.6274 DO - 10.3892/ol.2017.6274 ID - Yu2017 ER - TY - STD TI - Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet Oncology. 2016;387(10031). ID - ref14 ER - TY - JOUR AU - Kaufman, H. L. AU - Russell, J. AU - Hamid, O. AU - Bhatia, S. AU - Terheyden, P. AU - Dangelo, S. P. PY - 2016 DA - 2016// TI - Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30364-3 DO - 10.1016/S1470-2045(16)30364-3 ID - Kaufman2016 ER - TY - JOUR AU - Seiwert, T. Y. AU - Burtness, B. AU - Mehra, R. AU - Weiss, J. AU - Berger, R. AU - Eder, J. P. PY - 2016 DA - 2016// TI - Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30066-3 DO - 10.1016/S1470-2045(16)30066-3 ID - Seiwert2016 ER - TY - JOUR AU - Moehler, M. AU - Delic, M. AU - Goepfert, K. AU - Aust, D. AU - Grabsch, H. I. AU - Halama, N. PY - 2016 DA - 2016// TI - Immunotherapy in gastrointestinal cancer: recent results, current studies and future perspectives JO - Eur J Cancer VL - 59 UR - https://doi.org/10.1016/j.ejca.2016.02.020 DO - 10.1016/j.ejca.2016.02.020 ID - Moehler2016 ER - TY - JOUR AU - Savage, K. J. AU - Steidl, C. PY - 2016 DA - 2016// TI - Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them JO - Expert Rev Hematol VL - 9 UR - https://doi.org/10.1080/17474086.2016.1242404 DO - 10.1080/17474086.2016.1242404 ID - Savage2016 ER - TY - STD TI - Hellmann MD, Gettinger SN, Goldman JW, Brahmer JR, Borghaei H, Chow LQ, et al. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Journal of Clinical Oncology. 2016;34(15_suppl):3001. ID - ref19 ER - TY - STD TI - Diaz LA, Marabelle A, Delord J-P, Shapira-Frommer R, Geva R, Peled N, Kim TW, Andre T, Cutsem EV, Guimbaud R, Jaeger D, Elez E, Yoshino T, Joe AK, Lam B, Gause CK, Pruitt SK, Kang SP, Le DT. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J. Clin. Oncol. 2017;35(15_suppl):3071. ID - ref20 ER - TY - STD TI - Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 2017;377(26):2531–44. ID - ref21 ER - TY - JOUR AU - Schuster, S. J. AU - Svoboda, J. AU - Chong, E. A. AU - Nasta, S. D. AU - Mato, A. R. AU - Anak, O. AU - Brogdon, J. L. AU - Pruteanu-Malinici, I. AU - Bhoj, V. AU - Landsburg, D. AU - Wasik, M. AU - Levine, B. L. AU - Lacey, S. F. AU - Melenhorst, J. J. AU - Porter, D. L. AU - June, C. H. PY - 2017 DA - 2017// TI - Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas JO - N. Engl. J. Med. VL - 377 UR - https://doi.org/10.1056/NEJMoa1708566 DO - 10.1056/NEJMoa1708566 ID - Schuster2017 ER - TY - JOUR AU - Wang, D. Y. AU - Salem, J. E. AU - Cohen, J. V. AU - Chandra, S. AU - Menzer, C. AU - Ye, F. PY - 2018 DA - 2018// TI - Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis JO - JAMA VL - 4 ID - Wang2018 ER - TY - STD TI - Ciren B, Wang X, Long Z. The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget. 2016;7(49). ID - ref24 ER - TY - STD TI - Kroschinsky F, Stölzel F, Bonin SV, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Critical Care. 2017;21(1). ID - ref25 ER - TY - STD TI - Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. ID - ref26 ER - TY - JOUR AU - Lee, D. W. AU - Gardner, R. AU - Porter, D. L. AU - Louis, C. U. AU - Ahmed, N. AU - Jensen, M. AU - Grupp, S. A. AU - Mackall, C. L. PY - 2014 DA - 2014// TI - Current concepts in the diagnosis and management of cytokine release syndrome JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-05-552729 DO - 10.1182/blood-2014-05-552729 ID - Lee2014 ER - TY - STD TI - Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England J Med. 2013;368:1509–18. ID - ref28 ER - TY - JOUR AU - Park, J. H. AU - Rivière, I. AU - Gonen, M. AU - Wang, X. AU - Sénéchal, B. AU - Curran, K. J. AU - Sauter, C. AU - Wang, Y. AU - Santomasso, B. AU - Mead, E. AU - Roshal, M. AU - Maslak, P. AU - Davila, M. AU - Brentjens, R. J. AU - Sadelain, M. PY - 2018 DA - 2018// TI - Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia JO - N. Engl. J. Med. VL - 378 UR - https://doi.org/10.1056/NEJMoa1709919 DO - 10.1056/NEJMoa1709919 ID - Park2018 ER - TY - STD TI - Center for Drug Evaluation and Research. Approved Drugs - FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome [Internet]. U S Food and Drug Administration Home Page. Center for Drug Evaluation and Research; 2017 [cited 2018 Nov 17]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm574154.htm. UR - https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm574154.htm ID - ref30 ER - TY - STD TI - Adverse effects from certain immunotherapies may be more common than initially reported. Healio. [cited 2019 Jan 7]. https://www.healio.com/hematology-oncology/lung-cancer/news/online/45aa720b-8739-4ada-bf35-9c7e9e75553c/adverse-effects-from-certain-immunotherapies-may-be-more-common-than-initially-reported. UR - https://www.healio.com/hematology-oncology/lung-cancer/news/online/45aa720b-8739-4ada-bf35-9c7e9e75553c/adverse-effects-from-certain-immunotherapies-may-be-more-common-than-initially-reported ID - ref31 ER - TY - JOUR AU - Johnson, D. B. AU - Sullivan, R. J. AU - Menzies, A. M. PY - 2017 DA - 2017// TI - Immune checkpoint inhibitors in challenging populations JO - Cancer VL - 123 UR - https://doi.org/10.1002/cncr.30642 DO - 10.1002/cncr.30642 ID - Johnson2017 ER - TY - STD TI - Melanoma Research Foundation. Advances in Melanoma Oncology - Mike Atkins, MD LinkedIn SlideShare. 2017 [cited 2019 Jan13. ID - ref33 ER - TY - STD TI - Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, et al. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. Journal for ImmunoTherapy of Cancer. BioMed Central; 2017 [cited 2019Jan7]. https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0241-6 UR - https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0241-6 ID - ref34 ER - TY - JOUR AU - Addario, B. J. AU - Fadich, A. AU - Fox, J. AU - Krebs, L. AU - Maskens, D. AU - Oliver, K. PY - 2018 DA - 2018// TI - Patient value: Perspectives from the advocacy community JO - Health Expect VL - 21 UR - https://doi.org/10.1111/hex.12628 DO - 10.1111/hex.12628 ID - Addario2018 ER - TY - JOUR AU - Azizi, M. AU - Elyasi, F. PY - 2017 DA - 2017// TI - Effective strategies for increasing the hope in patients with cancer: a review JO - Journal of Cellular Immunotherapy VL - 3 UR - https://doi.org/10.1016/j.jocit.2017.04.021 DO - 10.1016/j.jocit.2017.04.021 ID - Azizi2017 ER - TY - STD TI - Kolata G. ‘Desperation Oncology’: When Patients Are Dying, Some Cancer Doctors Turn to Immunotherapy. The New York Times. The New York Times; 2018 [cited 2019Jan7]. https://www.nytimes.com/2018/04/26/health/doctors-cancer-immunotherapy.html?rref=collection/sectioncollection/health&action=click&contentCollection=health®ion=rank&module=package&version=highlights&contentPlacement=5&pgtype=sectionfront UR - https://www.nytimes.com/2018/04/26/health/doctors-cancer-immunotherapy.html?rref=collection/sectioncollection/health&action=click&contentCollection=health%C2%AEion=rank&module=package&version=highlights&contentPlacement=5&pgtype=sectionfront ID - ref37 ER - TY - STD TI - Office of the Commissioner. Oncology Center of Excellence - Patient-Focused Drug Development. U S Food and Drug Administration Home Page. Center for Drug Evaluation and Research; 2018 [cited 2018Nov17]. https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/ucm544143.htm UR - https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/ucm544143.htm ID - ref38 ER - TY - JOUR AU - Detiček, A. AU - Locatelli, I. AU - Kos, M. PY - 2018 DA - 2018// TI - Patient access to medicines for rare diseases in European countries JO - Value Health VL - 21 UR - https://doi.org/10.1016/j.jval.2018.01.007 DO - 10.1016/j.jval.2018.01.007 ID - Detiček2018 ER - TY - JOUR AU - Diaby, V. AU - Ali, A. A. AU - Adunlin, G. AU - Kohn, C. G. AU - Montero, A. J. PY - 2016 DA - 2016// TI - Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients JO - Current Medical Research and Opinion VL - 32 UR - https://doi.org/10.1185/03007995.2016.1149056 DO - 10.1185/03007995.2016.1149056 ID - Diaby2016 ER - TY - JOUR AU - Willke, R. J. AU - Neumann, P. J. AU - Garrison, L. P. AU - Ramsey, S. D. PY - 2018 DA - 2018// TI - Review of recent US value frameworks – a health economics approach: an ISPOR special task force report JO - Value Health VL - 21 UR - https://doi.org/10.1016/j.jval.2017.12.011 DO - 10.1016/j.jval.2017.12.011 ID - Willke2018 ER - TY - JOUR AU - Cherny, N. I. AU - Sullivan, R. AU - Dafni, U. PY - 2015 DA - 2015// TI - A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society of Medical Oncology Magnitude of clinical benefit scale (ESMO-MCBS) JO - Ann Onc VL - 26 UR - https://doi.org/10.1093/annonc/mdv249 DO - 10.1093/annonc/mdv249 ID - Cherny2015 ER - TY - STD TI - Patient Pe rspective Value Framework. FasterCures. [2018Nov17]. https://www.fastercures.org/programs/patients-count/patient-perspective-value-framework/Open-Source Value Project. Innovation and Value Initiative. [cited 2018Nov17]. https://www.thevalueinitiative.org/open-source-value-project/ UR - https://www.thevalueinitiative.org/open-source-value-project/ ID - ref43 ER - TY - BOOK AU - Neumann, P. J. AU - Sanders, G. D. AU - Russell, L. B. AU - Siegel, J. E. AU - Ganiats, T. G. PY - 2016 DA - 2016// TI - Cost effectiveness in health and medicine PB - Oxford University Press CY - New York UR - https://doi.org/10.1093/acprof:oso/9780190492939.001.0001 DO - 10.1093/acprof:oso/9780190492939.001.0001 ID - Neumann2016 ER - TY - JOUR AU - Perfetto, E. M. PY - 2018 DA - 2018// TI - ISPOR’s Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients JO - Value in Health VL - 21 UR - https://doi.org/10.1016/j.jval.2017.12.002 DO - 10.1016/j.jval.2017.12.002 ID - Perfetto2018 ER - TY - STD TI - Cohen JT, Anderson JE, Neumann PH. Three sets of case studies suggest logic and consistency challenges with value frameworks. Value in Health. 2017;20:193–9. ID - ref46 ER - TY - JOUR AU - Bentley, T. G. K. AU - Cohen, J. T. AU - Elkin, E. B. AU - Huynh, J. AU - Mukherjea, A. AU - Neville, T. H. AU - Mei, M. AU - Copher, R. AU - Knoth, R. AU - Popescu, I. AU - Lee, J. AU - Zambrano, J. M. AU - Broder, M. S. PY - 2017 DA - 2017// TI - Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs JO - Value in Health VL - 20 UR - https://doi.org/10.1016/j.jval.2016.12.011 DO - 10.1016/j.jval.2016.12.011 ID - Bentley2017 ER - TY - STD TI - Gemmen E, Parmenter L. Special considerations for the analysis of patient-level Immuno-oncology data. Value & Outcomes Spotlight. 2018:23–4. ID - ref48 ER - TY - STD TI - Huang M, Latimer N, Zhang Y, et al. Estimating the Long-term outcomes associated with Immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Value & Outcomes Spotlight. 2018:28–30. ID - ref49 ER - TY - JOUR AU - Phillips, D. AU - Leiro, B. PY - 2018 DA - 2018// TI - Clinical outcome assessments: use of normative data in a pediatric rare disease JO - Value Health VL - 21 ID - Phillips2018 ER - TY - JOUR AU - Nestler-Parr, S. AU - Korchagina, D. AU - Toumi, M. PY - 2018 DA - 2018// TI - Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease special interest group JO - Value Health VL - 21 UR - https://doi.org/10.1016/j.jval.2018.03.004 DO - 10.1016/j.jval.2018.03.004 ID - Nestler-Parr2018 ER - TY - STD TI - ASCO, NCCN Provide Guidance on Understanding and Managing Immunotherapy Side Effects. ASCO Connection. 2018 [cited 2019Jan13]. ID - ref52 ER - TY - STD TI - Medscape Log In. [cited 2019Jan13]. https://www.medscape.com/viewarticle/889689 UR - https://www.medscape.com/viewarticle/889689 ID - ref53 ER - TY - JOUR AU - Lipscomb, J. AU - Drummond, M. AU - Fryback, D. PY - 2009 DA - 2009// TI - Retaining, and enhancing, the QALY JO - Value Health VL - 12 UR - https://doi.org/10.1111/j.1524-4733.2009.00518.x DO - 10.1111/j.1524-4733.2009.00518.x ID - Lipscomb2009 ER - TY - JOUR AU - Garrison, L. AU - Neumann, P. J. AU - Willke, R. J. PY - 2018 DA - 2018// TI - A health economics approach to US value assessment frameworks – summary and recommendations of the ISPOR special task force report JO - Value Health VL - 21 UR - https://doi.org/10.1016/j.jval.2017.12.009 DO - 10.1016/j.jval.2017.12.009 ID - Garrison2018 ER - TY - JOUR AU - Whittington, M. D. AU - Mcqueen, R. B. AU - Ollendorf, D. A. AU - Kumar, V. M. AU - Chapman, R. H. AU - Tice, J. A. PY - 2018 DA - 2018// TI - Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients with Relapsed or Refractory Leukemia JO - JAMA Pediatrics VL - 172 UR - https://doi.org/10.1001/jamapediatrics.2018.2530 DO - 10.1001/jamapediatrics.2018.2530 ID - Whittington2018 ER - TY - STD TI - Basch E. Toward a Patient-Centered Value Framework in Oncology. JAMA. 2016;315(9):2073–4. ID - ref57 ER - TY - JOUR AU - Mott, F. E. PY - 2017 DA - 2017// TI - Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions JO - Oncology and Therapy VL - 5 UR - https://doi.org/10.1007/s40487-016-0038-7 DO - 10.1007/s40487-016-0038-7 ID - Mott2017 ER - TY - JOUR AU - Devlin, N. J. AU - Lorgelly, P. K. PY - 2017 DA - 2017// TI - QALYs as a measure of value in cancer JO - J. Cancer Policy VL - 11 UR - https://doi.org/10.1016/j.jcpo.2016.09.005 DO - 10.1016/j.jcpo.2016.09.005 ID - Devlin2017 ER - TY - JOUR AU - Kovic, B. AU - Jin, X. AU - Kennedy, S. A. AU - Hylands, M. AU - Pedziwiatr, M. AU - Kuriyama, A. PY - 2018 DA - 2018// TI - Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis JO - JAMA Internal Medicine VL - 178 UR - https://doi.org/10.1001/jamainternmed.2018.4710 DO - 10.1001/jamainternmed.2018.4710 ID - Kovic2018 ER - TY - JOUR AU - Efthymiadou, O. AU - Mossman, J. AU - Kanavos, P. PY - 2018 DA - 2018// TI - Differentiation of Health-Related Quality of Life Outcomes Between Five Disease Areas: Results from An International Survey Of Patients JO - International Journal of Technology Assessment in Health Care VL - 34 UR - https://doi.org/10.1017/S0266462318000557 DO - 10.1017/S0266462318000557 ID - Efthymiadou2018 ER - TY - JOUR AU - Bottomley, A. AU - Pe, M. AU - Sloan, J. PY - 2016 DA - 2016// TI - Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30510-1 DO - 10.1016/S1470-2045(16)30510-1 ID - Bottomley2016 ER - TY - JOUR AU - Calvert, M. AU - Kyte, D. AU - Mercieca-Bebber, R. PY - 2018 DA - 2018// TI - Guidelines for inclusion of patient-reported outcomes in clinical trial protocols, The SPIRIT-PRO Extension JO - JAMA VL - 319 UR - https://doi.org/10.1001/jama.2017.21903 DO - 10.1001/jama.2017.21903 ID - Calvert2018 ER - TY - JOUR AU - Howie, L. J. AU - Singh, H. AU - King-Kallimanis, B. AU - Roydhouse, J. AU - Theoret, M. R. AU - Blumenthal, G. M. PY - 2018 DA - 2018// TI - Patient-reported outcomes in PD-1/PD-L1 inhibitor registration trials: FDA analysis of data submitted and future directions JO - Journal of Clinical Oncology VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.5_suppl.134 DO - 10.1200/JCO.2018.36.5_suppl.134 ID - Howie2018 ER - TY - STD TI - National Coverage Analysis (NCA) for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N). CMS.gov Centers for Medicare & Medicaid Services. [cited 2018Sep27]. https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=291 UR - https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=291 ID - ref65 ER - TY - STD TI - MEDCAC Meeting 8/22/2018 - Chimeric Antigen Receptor (CAR) T-Cell Therapy and Patient Reported Outcomes. CMS.gov Centers for Medicare & Medicaid Services. [cited 2018Sep27]. https://www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=76&NCAId=291&bc=gIAAAAAAQAAA& UR - https://www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=76&NCAId=291&bc=gIAAAAAAQAAA& ID - ref66 ER - TY - STD TI - CMS MEDCAC Voting Scores: https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/downloads/id76c.pdf, Accessed 20 Oct 2018. UR - https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/downloads/id76c.pdf ID - ref67 ER - TY - STD TI - CMS NCD website: https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=291&bc=gIAAAAAAQAAA&. Accessed 2 Oct 2018. UR - https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=291&bc=gIAAAAAAQAAA& ID - ref68 ER - TY - JOUR AU - Basch, E. AU - Deal, A. M. AU - Dueck, A. C. AU - Scher, H. I. AU - Kris, M. G. AU - Hudis, C. PY - 2017 DA - 2017// TI - Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine Cancer treatment JO - JAMA. VL - 318 UR - https://doi.org/10.1001/jama.2017.7156 DO - 10.1001/jama.2017.7156 ID - Basch2017 ER - TY - JOUR AU - Basch, E. PY - 2016 DA - 2016// TI - Toward a patient-centered value framework in oncology JO - JAMA. VL - 315 UR - https://doi.org/10.1001/jama.2016.4637 DO - 10.1001/jama.2016.4637 ID - Basch2016 ER - TY - JOUR AU - Ben-Aharon, O. AU - Magnezi, R. AU - Leshno, M. AU - Goldstein, D. A. PY - 2018 DA - 2018// TI - Association of Immunotherapy with durable survival as defined by value frameworks for Cancer care JO - JAMA. VL - 4 ID - Ben-Aharon2018 ER - TY - STD TI - Harold Sox’s paper defining “comparative effectiveness research” from the Institute of Medicine to kick off this section. Sox HC. Med Care. 2010; 48: S7-S8. ID - ref72 ER - TY - JOUR AU - Garrison, L. P. AU - Neumann, P. J. AU - Erickson, P. AU - Marshall, D. AU - Mullins, C. D. PY - 2007 DA - 2007// TI - Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report JO - Value Health VL - 10 UR - https://doi.org/10.1111/j.1524-4733.2007.00186.x DO - 10.1111/j.1524-4733.2007.00186.x ID - Garrison2007 ER - TY - JOUR AU - Caro, J. J. AU - Briggs, A. H. AU - Siebert, U. AU - Kuntz, K. M. PY - 2012 DA - 2012// TI - Modeling good research practices--overview: a report of the ISPOR-SMDM modeling good research practices task Force-1 JO - Med Decis Mak VL - 32 UR - https://doi.org/10.1177/0272989X12454577 DO - 10.1177/0272989X12454577 ID - Caro2012 ER - TY - STD TI - Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahm M, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093–103. ID - ref75 ER - TY - STD TI - Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD. Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical. Med. Decis. Making 2018;38(7):767–777. ID - ref76 ER - TY - JOUR AU - Lakdawalla, D. N. AU - Doshi, J. A. AU - Garrison, L. P. AU - Phelps, C. E. AU - Basu, A. AU - Danzon, P. M. PY - 2018 DA - 2018// TI - Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] JO - Value in Health VL - 21 UR - https://doi.org/10.1016/j.jval.2017.12.007 DO - 10.1016/j.jval.2017.12.007 ID - Lakdawalla2018 ER - TY - STD TI - Mullins CD, Abdulhalim AM, Lavallee DC. Continuous Patient Engagement in Comparative Effectiveness Research. JAMA. 2012;307(15):1587–8.  ID - ref78 ER - TY - JOUR AU - Perfetto, E. M. AU - Oehrlein, E. M. AU - Boutin, M. AU - Reid, S. AU - Gascho, E. PY - 2017 DA - 2017// TI - Value to Whom? The Patient Voice in the Value Discussion JO - Value in Health VL - 20 UR - https://doi.org/10.1016/j.jval.2016.11.014 DO - 10.1016/j.jval.2016.11.014 ID - Perfetto2017 ER - TY - JOUR AU - Emens, L. A. AU - Ascierto, P. A. AU - Darcy, P. K. AU - Demaria, S. AU - Eggermont, A. M. AU - Redmond, W. L. PY - 2017 DA - 2017// TI - Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape JO - European Journal of Cancer VL - 81 UR - https://doi.org/10.1016/j.ejca.2017.01.035 DO - 10.1016/j.ejca.2017.01.035 ID - Emens2017 ER -